| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Ligands in Cancer Cells1
Cancer Center, The Burnham Institute, La Jolla, California 92037
The peroxisome proliferator-activated receptor
(PPAR
) is a nuclear receptor family member that can form a heterodimeric complex with retinoid X receptor (RXR) and initiate transcription of target genes. In this study, we have examined the effects of the PPAR
ligand ciglitazone and the RXR ligand SR11237 on growth and induction of retinoic acid receptor (RAR) ß expression in breast and lung cancer cells. Our results demonstrated that ciglitazone and SR11237 cooperatively inhibited the growth of ZR-75-1 and T-47D breast cancer and Calu-6 lung cancer cells. Gel shift analysis indicated that PPAR
, in the presence of RXR, formed a strong complex with a retinoic acid response element (ß retinoic acid response element) in the RARß promoter. In reporter gene assays, RXR ligands and ciglitazone, but not the PPAR
ligand 15d-PGJ2, cooperatively promoted the transcriptional activity of the ß retinoic acid response element. Ciglitazone, but not 15d-PGJ2, strongly induced RARß expression in human breast and lung cancer cell lines when used together with SR11237. The induction of RARß expression by the ciglitazone and SR11237 combination was diminished by a PPAR
-selective antagonist, bisphenol A diglycidyl ether. All-trans-retinoic acid or the combination of ciglitazone and SR11237 was able to induce RARß in all-trans-retinoic acid-resistant MDA-MB-231 breast cancer cells only when the orphan receptor chick ovalbumin upstream promoter transcription factor was expressed, or in the presence of the histone deacetylase inhibitor trichostatin A. These studies indicate the existence of a novel RARß-mediated signaling pathway of PPAR
action, which may provide a molecular basis for developing novel therapies involving RXR and PPAR
ligands in potentiating antitumor responses.
This article has been cited by other articles:
![]() |
E Memili, D Peddinti, L A Shack, B Nanduri, F McCarthy, H Sagirkaya, and S C Burgess Bovine germinal vesicle oocyte and cumulus cell proteomics Reproduction, June 1, 2007; 133(6): 1107 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schupp, J. C. Curtin, R. J. Kim, A. N. Billin, and M. A. Lazar A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-{gamma} Activity Mol. Pharmacol., May 1, 2007; 71(5): 1251 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Govindarajan, L. Ratnasinghe, D. L. Simmons, E. R. Siegel, M. V. Midathada, L. Kim, P. J. Kim, R. J. Owens, and N. P. Lang Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes J. Clin. Oncol., April 20, 2007; 25(12): 1476 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Stebbins, D. Jung, M. Leone, X.-k. Zhang, and M. Pellecchia A Structure-based Approach to Retinoid X Receptor-{alpha} Inhibition J. Biol. Chem., June 16, 2006; 281(24): 16643 - 16648. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-c. Xu, J. J. Lee, T.-T. Wu, A. Hoque, J. A. Ajani, and S. M. Lippman Increased Retinoic Acid Receptor-{beta}4 Correlates In vivo with Reduced Retinoic Acid Receptor-{beta}2 in Esophageal Squamous Cell Carcinoma Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 826 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Kolluri, M. Corr, S. Y. James, M. Bernasconi, D. Lu, W. Liu, H. B. Cottam, L. M. Leoni, D. A. Carson, and X.-k. Zhang The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis PNAS, February 15, 2005; 102(7): 2525 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Strakova, J. Ehrmann, P. Dzubak, J. Bouchal, and Z. Kolar The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-{gamma} Ciglitazone Affects Human Glioblastoma Cell Lines J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1239 - 1247. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |